Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atosiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 6/20 | 0.71 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.68 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.68 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atosiban SCHEMBL29522709 | 1.00 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL19712221 | 1.00 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL34316 | 1.00 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL4410202 | 0.98 | OXTR (0.69) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL3138542 | 0.98 | OXTR (0.69) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL4414282 | 0.97 | OXTR (0.67) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL21255736 | 0.95 | OXTR (0.72) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL26813594 | 0.90 | OXTR (0.58) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15511860 | 0.89 | OXTR (0.81) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL13723569 | 0.88 | OXTR (0.56) | OXTRAVPR1AAVPR1BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466851-B2 | Manufacture of disulfide bonded peptides | BACHEM HOLDING AG (CH) | 2025-11-11 | — | — | US | disclosed |
| CN-119936214-A | Detection method of atosiban key isomer | 四川科伦药物研究院有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4455880-A1 | METHOD, APPARATUS, DEVICE, AND MEDIUM FOR ACTION EXECUTION | DOUYIN VISION CO., LTD. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240330707-A1 | METHOD, APPARATUS, DEVICE, AND MEDIUM FOR ACTION EXECUTION | DOUYIN VISION CO LTD (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-116333053-A | Atosiban and method for inhibiting formation of polymeric impurities | 海南中和药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116173180-A | Use of atosiban injection solution and stabilization method | 海南中和药业股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115038711-B | Synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115038711-A | Synthetic method of atosiban | 湖北健翔生物制药有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-20220213139-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | BACHEM HOLDING AG (CH) | 2022-07-07 | — | — | US | disclosed |
| WO-2020212477-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | BACHEM HOLDING AG (CH) | 2020-10-22 | — | — | WO | disclosed |
| EP-3257863-A1 | FLOUROUS METABOLICALLY STABLE PEPTIDE ANALOGS | Université de Strasbourg (FR) | 2017-12-20 | — | — | EP | disclosed |
| US-9757424-B2 | Compositions and methods of treating gliomas | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170198292-A1 | Methods and Compositions for Modulating Lung Cancer Tumor Initiating Cells (TIC), and Oxytocin Receptor (OXTR) Modulatory Agents for Use in Practicing the Same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-07-13 | — | — | US | disclosed |
| WO-2016007421-A1 | METHODS AND COMPOSITIONS FOR MODULATING LUNG CANCER TUMOR INITIATING CELLS (TIC), AND OXYTOCIN RECEPTOR (OXTR) MODULATORY AGENTS FOR USE IN PRACTICING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20140235556-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | BIOMED VALLEY DISCOVERIES, INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140066373-A1 | TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | AMPLA PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | ADRB3, FFAR3, SLC6A4 | OXTR 771/4885AVPR1A 698/4885AVPR1B 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.